WO2017186197A1 - Salts of lenvatinib - Google Patents
Salts of lenvatinib Download PDFInfo
- Publication number
- WO2017186197A1 WO2017186197A1 PCT/CZ2017/000030 CZ2017000030W WO2017186197A1 WO 2017186197 A1 WO2017186197 A1 WO 2017186197A1 CZ 2017000030 W CZ2017000030 W CZ 2017000030W WO 2017186197 A1 WO2017186197 A1 WO 2017186197A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- lenvatinib
- salt
- accordance
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to solid forms of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]- 7-methoxy-quinoline-6-carboxamide (CAS No. 417716-92-8) of formula I, known as lenvatinib, methods of their preparation and use in a drug form.
- the drug with the name Lenvima which contains lenvatinib mesylate, has been approved by the Food and Drug Administration (FDA) for the treatment of locally recurrent or metastatic, progressive thyroid cancer, resistant to radioactive iodine.
- FDA Food and Drug Administration
- the patent application WO 2006/137474 describes preparation and characterization methods of amorphous forms of lenvatinib esylate and lenvatinib mesylate.
- the patent application WO 2014/098176 describes preparation and characterization methods of an amorphous form of lenvatinib free base.
- Pharmaceutical compositions containing lenvatinib or its salts are disclosed in the patent applications WO 2006/030826 and WO 2011/021597.
- Many pharmaceutical solid compounds can form salts or cocrystals with suitable counterions and thus exist in various crystalline forms that have different crystal units and thus different physicochemical properties as the melting point, solubility, dissolution rate as well as biological availability.
- several solid- state analytic methods can be used, e.g. X-ray powder diffraction, solid-state NMR, Raman spectroscopy as well as thermoanalytic methods.
- the object of the invention are pharmaceutically acceptable salts of lenvatinib and methods of their preparation.
- These solid forms of lenvatinib are prepared through a reaction of lenvatinib free base with suitable inorganic or organic acids in a suitable solvent or mixtures of solvents.
- the prepared solid forms have suitable physicochemical characteristics for use in the pharmaceutical industry and formulation of new drug forms.
- An object of this invention is the salt of lenvatinib with phosphoric acid, tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid.
- Another object of the invention is the salt of lenvatinib with phosphoric acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 8.1; 11.3; 20.3; 21.5 and 25.8 ⁇ 0,2° 2-theta.
- the salt of lenvatinib with phosphoric acid is further characterized by the differential scanning calorimetry curve with the melting point at 178°C.
- Another object of the invention is a preparation method of the salt of lenvatinib with phosphoric acid wherein the free base of lenvatinib is dissolved in a suitable solvent and phosphoric acid is added subsequently.
- a suitable solvent is a solvent selected from the group consisting of aliphatic C1-C4 alcohols, ketones, esters, nitriles, water or their mixtures, preferably from acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
- Another object of the invention is the salt of lenvatinib with tartaric acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 4.0; 11.1; 15.2; 20.2 and 22.4 ⁇ 0.2° 2-theta.
- the salt of lenvatinib with tartaric acid is further characterized by the differential scanning calorimetry curve with the melting point at 169°C.
- Another object of the invention is the salt of lenvatinib with citric acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 8.0; 12.0; 13.9; 20.0 and 24.3 ⁇ 0.2° 2-theta.
- the salt of lenvatinib with citric acid is further characterized by the differential scanning calorimetry curve with the melting point at 148°C.
- Another object of the invention is the salt of lenvatinib with camphorsulfonic acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 4.6; 12.8; 14.4; 16.4; 18.1; 18.5; 20.1 and 25.8 ⁇ 0.2° 2-theta.
- the salt of lenvatinib with camphorsulfonic acid is further characterized by the differential scanning calorimetry curve with the melting point at 211°C.
- Another object of the invention is the salt of lenvatinib with isethionic acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 5.1; 9.4; 14.6; 17.3; 20.1 and 25.4 ⁇ 0.2° 2-theta.
- the salt of lenvatinib with isethionic acid is further characterized by the differential scanning calorimetry curve with the melting point at 144°C.
- Another object of the invention is the salt of lenvatinib with naphthalenedisulfonic acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 5.8; 10.2; 13.5; 15.6; 19.9 and 23.3 ⁇ 0.2° 2-theta.
- the salt of lenvatinib with naphthalenedisulfonic acid is further characterized by the differential scanning calorimetry curve with the melting point at 155°C.
- Another object of the invention is a preparation method of a salt of lenvatinib with an acid in accordance with the present invention wherein the free base of lenvatinib is dissolved in a suitable solvent together with an acid that is selected from the group consisting of tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid.
- a suitable solvent is a solvent selected from the group consisting of aliphatic C1-C4 alcohols, ketones, esters, nitriles, water or their mixtures, preferably from acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
- Another object of the invention is the use of a solid form of a salt of lenvatinib with an acid in accordance with the present invention for the preparation of a pharmaceutical composition.
- Another object of the invention is a pharmaceutical composition comprising a solid form of a salt of lenvatinib with an acid in accordance with the present invention and at least one pharmaceutically acceptable excipient.
- Figure 1 X-ray powder pattern of lenvatinib phosphate
- This invention provides several crystalline salts of lenvatinib, the obtained crystalline forms exhibiting a lower melting point than the crystalline lenvatinib mesylate used in the drug Lenvima.
- the invention prefers crystalline forms of salts of lenvatinib with counterfoils of acids whose salts are physiologically common, or they represent intermediates of metabolites in biochemical processes. These compounds comprise phosphoric acid, citric acid and tartaric acid.
- An object of this invention are solid forms of lenvatinib with phosphoric acid, tartaric acid, naphthalenedisulfonic acid, citric acid, camphorsulfonic acid and isethionic acid in various molar ratios. Within the invention, 1 :1 molar ratios are preferred.
- Solid forms of lenvatinib with these acids can be prepared in adequate ratios and yields with high chemical purity in a crystalline or amorphous form.
- solid forms can be both anhydrous and/or non-solvated, and they can have the form of hydrates/solvates of the respective solvents.
- the prepared solid forms of lenvatinib may have various internal arrangements (polymorphism) with different physicochemical properties depending on the conditions of their preparation. For this reason, the invention relates to individual crystals or their mixtures in any ratio.
- the preparation of the solid forms of lenvatinib in accordance with the present invention is carried out through a reaction of levantinib base with phosphoric acid, tartaric acid, naphthalenedisulfonic acid, citric acid, camphorsulfonic acid and isethionic acid.
- the reaction is conducted in a suitable solvent, which can be ketones, esters, ethers, amides, nitriles or organic acids, alcohols, aliphatic and aromatic hydrocarbons, chlorinated hydrocarbons, water or their mixtures. Aliphatic C1-C4 alcohols, ketones, esters, nitriles or their mixtures are preferred.
- the most commonly used solvents are acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
- the final product is typically precipitated or crystallized at temperatures in the range of - 30 C to the boiling point of the solvent.
- Lenvatinib free base (form B) was prepared in accordance with the process disclosed in the patent application WO 2004/101526. Differential scanning calorimetry (DSC) was applied to measure the melting point of crystalline form B of lenvatinib free base of 204°C. Crystalline salt of lenvatinib with methanesulfonic acid (form C) was prepared according to the process disclosed in the patent application WO 2005/063713. Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline salt of lenvatinib with methanesulfonic acid (form C) of 238°C.
- the crystalline form of lenvatinib phosphate (prepared according to Example 1) is Characterized by the reflections presented in Table 1.
- Table 1 includes reflections whose relative intensity value is higher than 1%.
- Characteristic diffraction peaks of the crystalline form of lenvatinib phosphate in accordance with the present invention with the use of CuKa radiation are: 8.1; 11.3; 20.3; 21.5 and 25.8 ⁇ 0,2° 2-theta.
- the X-ray powder pattern is shown in Fig. 1.
- DSC Differential scanning calorimetry
- the crystalline form of lenvatinib tartrate (prepared according to Example 2) is characterized by the reflections presented in Table 2.
- Table 2 includes reflections whose relative intensity value is higher than 1%.
- Characteristic diffraction peaks of the crystalline form of lenvatinib tartrate in accordance with the present invention with the use of CuK radiation are: 4.0; 11.1; 15.2; 20.2 and 22.4 ⁇ 0.2° 2-theta.
- the X-ray powder pattern is shown in Fig. 2.
- DSC Differential scanning calorimetry
- the crystalline form of lenvatinib tartrate (prepared according to Example 3) is characterized by the reflections presented in Table 3.
- Table 3 includes reflections whose relative intensity value is higher than 1%.
- Characteristic diffraction peaks of the crystalline form of lenvatinib citrate in accordance with the present invention with the use of CuKa radiation are: 8.0; 12.0; 13.9; 20.0 and 24.3 ⁇ 0.2° 2-theta.
- the X-ray powder pattern is shown in Fig. 3.
- DSC Differential scanning calorimetry
- the crystalline form of lenvatinib camphorsulfonate (prepared according to Example 4) is characterized by the reflections presented in Table 4.
- Table 4 includes reflections whose relative intensity value is higher than 1%.
- Characteristic diffraction peaks of the crystalline form of lenvatinib camphorsulfonate in accordance with the present invention with the use of CuKa radiation are: 4.6; 12.8; 14.4; 16.4; 18.1; 18.5; 20.1 and 25.8 ⁇ 0.2° 2-theta.
- the X-ray powder pattern is shown in Fig. 4.
- DSC Differential scanning calorimetry
- the crystalline form of lenvatinib isethionate (prepared according to Example 5) is characterized by the reflections presented in Table 5.
- Table 5 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib isethionate in accordance with the present invention with the use of CuKa radiation are: 5.1; 9.4; 14.6; 17.3; 20.1 and 25.4 ⁇ 0.2° 2-theta.
- the X-ray powder pattern is shown in Fig. 5. Table 5
- DSC Differential scanning calorimetry
- the crystalline form of lenvatinib naphthalenedisulfonate (prepared according to Example 6) is characterized by the reflections presented in Table 6.
- Table 6 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib naphthalenedisulfonate in accordance with the present invention with the use of CuKa radiation are: 5.8; 10.2; 13.5; 15.6; 19.9 and 23.3 ⁇ 0.2° 2-theta.
- the X-ray powder pattern is shown in Fig. 6. Table 6
- DSC Differential scanning calorimetry
- the solid forms of the salts of lenvatinib prepared in accordance with the present invention can be used for the preparation of pharmaceutical compositions, especially solid drug forms, e.g. tablets or capsules.
- Such pharmaceutical compositions can contain at least one excipient from the group of fillers (e.g. lactose), binders (e.g. microcrystalline cellulose), disintegrants (e.g. sodium salt of croscarmellose), lubricants (e.g. magnesium stearate), surfactants etc.
- a salt of lenvatinib can be mixed with the above mentioned excipients, screened through a sieve and the resulting mixture can be tabletted or filled into capsules.
- the tablets can be further coated with common coating compounds, e.g. polyvinyl alcohol or polyethylene glycol.
- the diffractograms were obtained using an X'PERT PRO MPD PANalytical powder diffractometer, used radiation CuKa ( ⁇ -01542 nm (1.542 A)), excitation voltage: 45 kV, anode current: 40 mA, measured range: 2 - 40° 2 ⁇ , increment: 0.01° 2 ⁇ at the dwell time at a reflection of 0.5 s, the measurement was carried out with a flat sample with the area/thickness of 10/0.5 mm.
- a 10mm mask and a 1/4° fixed anti-dispersion slit were used.
- the irradiated area of the sample is 10 mm, programmable divergence slits were used.
- Impurities were separated from the prepared salts of lenvatinib on an Ascentis Express CI 8 column, 2.7 um, 4.6 x 100 mm with the use of the mobile phase gradient:
- the amount of 10.0 mg of the tested substance is dissolved in 100% methanol. It is put in an ultrasonic bath for 5 min and after cooling to the laboratory temperature it is diluted with the same solvent to 10.0 ml.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to solid forms of 4-[3-chloro-4- (cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide (CAS No.417716-92-8) of formula I, known as lenvatinib, with an acid that is selected from the group consisting of phosphoric acid, tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid. Other objects are preparation methods of a salt of lenvatinib with the above mentioned acids and its use in a drug form. The drug with the name Lenvima, which contains lenvatinib mesylate, has been approved by the Food and Drug Administration (FDA) for the treatment of locally recurrent or metastatic, progressive thyroid cancer, resistant to radioactive iodine.
Description
Salts of lenvatinib
Field of the Invention
The invention relates to solid forms of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]- 7-methoxy-quinoline-6-carboxamide (CAS No. 417716-92-8) of formula I, known as lenvatinib, methods of their preparation and use in a drug form.
(I)
The drug with the name Lenvima, which contains lenvatinib mesylate, has been approved by the Food and Drug Administration (FDA) for the treatment of locally recurrent or metastatic, progressive thyroid cancer, resistant to radioactive iodine.
Background Art Preparation of lenvatinib and its isolation was first described in the patent application WO 0232872, in Example 368. The patent application WO 2004/101526 described preparation and characterization methods of two crystalline forms of lenvatinib free base (form A, B). The patent application WO 2005/063713 described preparation and characterization methods of crystalline salts of lenvatinib, in particular lenvatinib hydrochloride, hydrobromide, p- toluenesulfonate, sulphate, esylate, three polymorphic forms of lenvatinib mesylate (form A, B and C) and several mesylate and esylate solvates. The patent application WO 2006/137474 describes preparation and characterization methods of amorphous forms of lenvatinib esylate and lenvatinib mesylate. The patent application WO 2014/098176 describes preparation and characterization methods of an amorphous form of lenvatinib free base. Pharmaceutical compositions containing lenvatinib or its salts are disclosed in the patent applications WO 2006/030826 and WO 2011/021597.
Many pharmaceutical solid compounds can form salts or cocrystals with suitable counterions and thus exist in various crystalline forms that have different crystal units and thus different physicochemical properties as the melting point, solubility, dissolution rate as well as biological availability. To distinguish individual solid phases of a compound, several solid- state analytic methods can be used, e.g. X-ray powder diffraction, solid-state NMR, Raman spectroscopy as well as thermoanalytic methods.
Discovering new solid phases (salts and cocrystals) of an active pharmaceutical ingredient offers an opportunity to select a suitable modification with desired physicochemical properties and processability and improve the characteristics of the chemical product. For this reason, there is an obvious need of novel solid forms (salts and cocrystals) of lenvatinib.
Disclosure of the Invention
The object of the invention are pharmaceutically acceptable salts of lenvatinib and methods of their preparation. These solid forms of lenvatinib are prepared through a reaction of lenvatinib free base with suitable inorganic or organic acids in a suitable solvent or mixtures of solvents. The prepared solid forms have suitable physicochemical characteristics for use in the pharmaceutical industry and formulation of new drug forms.
An object of this invention is the salt of lenvatinib with phosphoric acid, tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid.
Another object of the invention is the salt of lenvatinib with phosphoric acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 8.1; 11.3; 20.3; 21.5 and 25.8 ± 0,2° 2-theta. In some embodiments, the salt of lenvatinib with phosphoric acid is further characterized by the differential scanning calorimetry curve with the melting point at 178°C.
Another object of the invention is a preparation method of the salt of lenvatinib with phosphoric acid wherein the free base of lenvatinib is dissolved in a suitable solvent and phosphoric acid is added subsequently. A suitable solvent is a solvent selected from the group consisting of aliphatic C1-C4 alcohols, ketones, esters, nitriles, water or their mixtures, preferably from acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures. Another object of the invention is the salt of lenvatinib with tartaric acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 4.0; 11.1; 15.2; 20.2 and 22.4 ± 0.2° 2-theta. In some embodiments, the salt of lenvatinib with
tartaric acid is further characterized by the differential scanning calorimetry curve with the melting point at 169°C.
Another object of the invention is the salt of lenvatinib with citric acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 8.0; 12.0; 13.9; 20.0 and 24.3 ± 0.2° 2-theta. In some embodiments, the salt of lenvatinib with citric acid is further characterized by the differential scanning calorimetry curve with the melting point at 148°C.
Another object of the invention is the salt of lenvatinib with camphorsulfonic acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 4.6; 12.8; 14.4; 16.4; 18.1; 18.5; 20.1 and 25.8 ± 0.2° 2-theta. In some embodiments, the salt of lenvatinib with camphorsulfonic acid is further characterized by the differential scanning calorimetry curve with the melting point at 211°C.
Another object of the invention is the salt of lenvatinib with isethionic acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 5.1; 9.4; 14.6; 17.3; 20.1 and 25.4 ± 0.2° 2-theta. In some embodiments, the salt of lenvatinib with isethionic acid is further characterized by the differential scanning calorimetry curve with the melting point at 144°C.
Another object of the invention is the salt of lenvatinib with naphthalenedisulfonic acid, exhibiting the characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 5.8; 10.2; 13.5; 15.6; 19.9 and 23.3 ± 0.2° 2-theta. In some embodiments, the salt of lenvatinib with naphthalenedisulfonic acid is further characterized by the differential scanning calorimetry curve with the melting point at 155°C.
Another object of the invention is a preparation method of a salt of lenvatinib with an acid in accordance with the present invention wherein the free base of lenvatinib is dissolved in a suitable solvent together with an acid that is selected from the group consisting of tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid. A suitable solvent is a solvent selected from the group consisting of aliphatic C1-C4 alcohols, ketones, esters, nitriles, water or their mixtures, preferably from acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
Another object of the invention is the use of a solid form of a salt of lenvatinib with an acid in accordance with the present invention for the preparation of a pharmaceutical composition.
Another object of the invention is a pharmaceutical composition comprising a solid form of a salt of lenvatinib with an acid in accordance with the present invention and at least one pharmaceutically acceptable excipient. Brief description of the Drawings
Figure 1: X-ray powder pattern of lenvatinib phosphate
Figure 2: X-ray powder pattern of lenvatinib tartrate
Figure 3: X-ray powder pattern of lenvatinib citrate
Figure 4: X-ray powder pattern of lenvatinib camphorsulfonate
Figure 5: X-ray powder pattern of lenvatinib isethionate
Figure 6: X-ray powder pattern of lenvatinib naphthalenedisulfonate
Detailed description of the Invention
Although preparation of a salt by a reaction of an acid and base is a well-known method, it is always a problem to obtain the required salts in the solid phase and purity corresponding to the demands for their pharmaceutical use. Biological availability greatly depends on whether a crystalline or amorphous product is obtained. An amorphous product is usually more readily soluble, it cannot often be obtained in the required quality and it is also often unstable. Conversely, compared to the amorphous form, a crystalline product is often stable, its required purity is easier to achieve and it dissolves more slowly. The problem may be solved by crystalline forms of active pharmaceutical ingredients with a lower melting point when such crystal arrangement guarantees higher solubility of the crystalline form, or by the use of the amorphous form of the active pharmaceutical ingredient.
This invention provides several crystalline salts of lenvatinib, the obtained crystalline forms exhibiting a lower melting point than the crystalline lenvatinib mesylate used in the drug Lenvima. The invention prefers crystalline forms of salts of lenvatinib with counterfoils of acids whose salts are physiologically common, or they represent intermediates of metabolites in biochemical processes. These compounds comprise phosphoric acid, citric acid and tartaric acid.
An object of this invention are solid forms of lenvatinib with phosphoric acid, tartaric acid, naphthalenedisulfonic acid, citric acid, camphorsulfonic acid and isethionic acid in various molar ratios. Within the invention, 1 :1 molar ratios are preferred.
Solid forms of lenvatinib with these acids can be prepared in adequate ratios and yields with high chemical purity in a crystalline or amorphous form.
These solid forms can be both anhydrous and/or non-solvated, and they can have the form of hydrates/solvates of the respective solvents.
The prepared solid forms of lenvatinib may have various internal arrangements (polymorphism) with different physicochemical properties depending on the conditions of their preparation. For this reason, the invention relates to individual crystals or their mixtures in any ratio.
These solid forms are suitable for the preparation of lenvatinib with a high chemical purity. The preparation of the solid forms of lenvatinib in accordance with the present invention is carried out through a reaction of levantinib base with phosphoric acid, tartaric acid, naphthalenedisulfonic acid, citric acid, camphorsulfonic acid and isethionic acid. The reaction is conducted in a suitable solvent, which can be ketones, esters, ethers, amides, nitriles or organic acids, alcohols, aliphatic and aromatic hydrocarbons, chlorinated hydrocarbons, water or their mixtures. Aliphatic C1-C4 alcohols, ketones, esters, nitriles or their mixtures are preferred. The most commonly used solvents are acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
The final product is typically precipitated or crystallized at temperatures in the range of - 30 C to the boiling point of the solvent.
Lenvatinib free base (form B) was prepared in accordance with the process disclosed in the patent application WO 2004/101526. Differential scanning calorimetry (DSC) was applied to measure the melting point of crystalline form B of lenvatinib free base of 204°C. Crystalline salt of lenvatinib with methanesulfonic acid (form C) was prepared according to the process disclosed in the patent application WO 2005/063713. Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline salt of lenvatinib with methanesulfonic acid (form C) of 238°C.
The crystalline form of lenvatinib phosphate (prepared according to Example 1) is Characterized by the reflections presented in Table 1. Table 1 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib phosphate in accordance with the present invention with the use of CuKa
radiation are: 8.1; 11.3; 20.3; 21.5 and 25.8 ± 0,2° 2-theta. The X-ray powder pattern is shown in Fig. 1.
Table 1
Interplanar spacing [A]
Position [°2Th.] [A]=0.1nm Rel. intensity [%]
2.78 31.813 21.3
5.46 16.186 50.3
8.11 10.892 88.0
10.76 8.220 46.3
1 1.35 7.793 ; 100.0
12.40 7.130 15.9
12.98 6.817 13.8
14.64 6.046 13.3
16.22 5.461 16.5
17.42 5.088 28.2
18.79 4.718 21.0
20.27 4.378 40.4
21.54 4.121 55.3
22.31 3.981 22.6
22.84 3.890 14.4
23.82 3.733 55.2
24.21 3.673 54.1
25.72 3.461 60.9
26.41 3.372 53.0
26.94 3.307 57.5
28.14 3.169 16.3
29.82 2.994 5.7
30.29 2.948 7.2
32.45 2.757 40.2
38.06 2.362 7.8
Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline form of lenvatinib phosphate of 178°C.
The crystalline form of lenvatinib tartrate (prepared according to Example 2) is characterized by the reflections presented in Table 2. Table 2 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib tartrate in accordance with the present invention with the use of CuK radiation are: 4.0; 11.1; 15.2; 20.2 and 22.4 ± 0.2° 2-theta. The X-ray powder pattern is shown in Fig. 2.
Table 2
Interplanar spacing [A]
Position [°2Th.] [A]=0.1nm Rel. intensity [%]
4.04 21.837 100.0
5.51 16.039 10.8
6.77 13.045 12.0
7.07 12.497 21.2
8.20 10.777 38.6
10.09 8.759 15.0
11.10 7.965 86.2
12.07 7.325 60.7
13.55 6.529 16.0
14.21 6.230 17.4
15.17 5.835 58.7
16.42 5.395 24.6
17.49 5.067 16.7
18.83 4.710 6.9
20.21 4.391 25.3
21.89 4.057 23.4
22.42 3.963 31.8
23.33 3.810 15.3
24.73 3.598 8.4
25.45 3.496 8.1
26.39 3.374 10.2
27.43 3.249 13.8
27.80 3.207 11.1
28.41 3.139 16.9
29.16 3.060 6.2
30.61 2.919 5.3
31.10 2.873 7.0
Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline form of lenvatinib tartrate of 169°C.
The crystalline form of lenvatinib tartrate (prepared according to Example 3) is characterized by the reflections presented in Table 3. Table 3 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib citrate in accordance with the present invention with the use of CuKa radiation are: 8.0; 12.0; 13.9; 20.0 and 24.3 ± 0.2° 2-theta. The X-ray powder pattern is shown in Fig. 3.
Table 3
Interplanar spacing [A]
Position [°2Th.] [A]=0.1nm Rel. intensity [%]
3.96 22.296 21.4
6.86 12.869 14.6
7.98 11.064 100.0
9.00 9.823 7.6
11.99 7.377 38.1
13.36 6.624 16.6
13.91 6.361 28.4
15.25 5.806 17.4
17.31 5.118 7.0
18.07 4.904 6.4
18.59 4.769 14.2
19.99 4.438 33.4
20.79 4.269 20.4
22.78 3.901 12.1
24.28 3.663 16.3
25.46 3.496 4.8
25.91 3.436 4.7
26.97 3.303 8.0
31.09 2.875 3.9
31.47 2.840 3.6
Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline form of lenvatinib citrate of 148°C.
The crystalline form of lenvatinib camphorsulfonate (prepared according to Example 4) is characterized by the reflections presented in Table 4. Table 4 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib camphorsulfonate in accordance with the present invention with the use of CuKa radiation are: 4.6; 12.8; 14.4; 16.4; 18.1; 18.5; 20.1 and 25.8 ± 0.2° 2-theta. The X-ray powder pattern is shown in Fig. 4.
Table 4
Position [°2Th.] Interplanar spacing [A] Rel. intensity [%]
[A]=0.1nm
4.56 19.356 77.7
11.29 7.832 27.1
11.72 7.545 6.9
12.78 6.919 32.1
14.44 6.128 81.1
16.40 5.400 85.0
17.62 5.030 28.6
18.06 4.907 77.0
18.53 4.784 44.3
19.18 4.623 28.5
20.08 4.418 100.0
21.19 4.189 23.6
21.87 4.061 10.5
22.27 3.989 28.4
Position [°2Th.] Interplanar spacing [A] Rel. intensity [%]
[A]=0.1nm
22.52 3.945 20.8
23.47 3.787 7.9
24.20 3.675 29.8
24.56 3.622 24.4
25.07 3.549 9.2
25.81 3.449 37.1
26.39 3.375 19.8
27.23 3.272 12.4
27.85 3.201 4.7
28.72 3.106 9.6
29.67 3.009 12.4
30.26 2.951 8.7
30.95 2.887 10.7
31.84 2.808 10.4
32.76 2.731 4.7
33.94 2.639 4.5
35.10 2.554 4.6
36.43 2.464 4.5
Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline form of lenvatinib camphorsulfonate of 211 °C.
The crystalline form of lenvatinib isethionate (prepared according to Example 5) is characterized by the reflections presented in Table 5. Table 5 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib isethionate in accordance with the present invention with the use of CuKa radiation are: 5.1; 9.4; 14.6; 17.3; 20.1 and 25.4 ± 0.2° 2-theta. The X-ray powder pattern is shown in Fig. 5.
Table 5
Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline form of lenvatinib isethionate of 144°C.
The crystalline form of lenvatinib naphthalenedisulfonate (prepared according to Example 6) is characterized by the reflections presented in Table 6. Table 6 includes reflections whose relative intensity value is higher than 1%. Characteristic diffraction peaks of the crystalline form of lenvatinib naphthalenedisulfonate in accordance with the present invention with the use of CuKa radiation are: 5.8; 10.2; 13.5; 15.6; 19.9 and 23.3 ± 0.2° 2-theta. The X-ray powder pattern is shown in Fig. 6.
Table 6
Position Interplanar spacing [A]
[°2Th.] [A]=0.1nm Rel. intensity [%]
5.83 15.159 61.3
7.79 11.334 52.8
10.15 8.707 69.3
11.16 7.921 32.2
11.69 7.564 9.0
13.49 6.561 100.0
15.58 5.684 41.3
16.33 5.424 9.5
17.28 5.126 15.5
18.22 4.866 17.1
18.72 4.737 28.0
19.06 4.653 9.3
19.90 4.459 38.9
20.37 4.357 27.4
20.68 4.292 27.6
21.59 4.112 9.2
23.33 3.810 54.6
24.00 3.705 42.7
24.69 3.603 11.7
25.07 3.549 11.5
25.49 3.492 19.8
25.98 3.427 10.9
26.23 3.395 10.3
26.50 3.360 8.3
27.10 3.287 10.4
27.82 3.205 21.4
29.16 3.060 5.9
29.92 2.984 5.5
Differential scanning calorimetry (DSC) was applied to measure the melting point of the crystalline form of lenvatinib naphthalenedisulfonate of 155°C.
The invention is clarified in a more detailed way using the embodiment examples below. These examples, which illustrate the preparation of solid forms of lenvatinib only have an illustrative character and do not restrict the scope of the invention in any respect.
The solid forms of the salts of lenvatinib prepared in accordance with the present invention can be used for the preparation of pharmaceutical compositions, especially solid drug forms, e.g. tablets or capsules. Such pharmaceutical compositions can contain at least one excipient from the group of fillers (e.g. lactose), binders (e.g. microcrystalline cellulose), disintegrants (e.g. sodium salt of croscarmellose), lubricants (e.g. magnesium stearate), surfactants etc. A salt of lenvatinib can be mixed with the above mentioned excipients, screened through a sieve and the resulting mixture can be tabletted or filled into capsules. The tablets can be further coated with common coating compounds, e.g. polyvinyl alcohol or polyethylene glycol. Experimental part
X-ray powder diffraction
The diffractograms were obtained using an X'PERT PRO MPD PANalytical powder diffractometer, used radiation CuKa (λ-01542 nm (1.542 A)), excitation voltage: 45 kV, anode current: 40 mA, measured range: 2 - 40° 2Θ, increment: 0.01° 2Θ at the dwell time at a reflection of 0.5 s, the measurement was carried out with a flat sample with the area/thickness of 10/0.5 mm. For the correction of the primary array 0.02 rad Soller slits, a 10mm mask and a 1/4° fixed anti-dispersion slit were used. The irradiated area of the sample is 10 mm, programmable divergence slits were used. For the correction of the secondary array 0.02 rad Soiler slits and a 5.0 anti-dispersion slit were used.
Differential Scanning Calorimetry (DSC)
The records of the solid crystalline lenvatinib salts were measured with the use of a DSC Pyris 1 device by Perkin Elmer. The sample charge in a standard Al pot was between 2.5-3 mg and the heating rate was 10°C7min. The temperature program that was used consists of 1 min of stabilization at the temperature of 0°C and then of heating up to 300°C at the heating rate bf lO C/min. As the carrier gas 4.0 N2 was used at the flow of 20 ml/min.
Ultra high-performance liquid chromatography (UHPLC)
Impurities were separated from the prepared salts of lenvatinib on an Ascentis Express CI 8 column, 2.7 um, 4.6 x 100 mm with the use of the mobile phase gradient:
A: 0.010 phosphate buffer (1.32 g) (NH4)2HP04 is dissolved in 1 1 of MQ water, pH of the solution is adjusted to the value of 7.5 ± 0.05 with the use of 50% phosphoric acid.
B: acetonitrile
sample solvent: 100% MeOH
detection: spectrophotometric 251 run
injected quantity: 0.5 μΐ
autosampler temperature: 18°C
column temperature: 35°C
analysis time: 12 min
sample preparation:
The amount of 10.0 mg of the tested substance is dissolved in 100% methanol. It is put in an ultrasonic bath for 5 min and after cooling to the laboratory temperature it is diluted with the same solvent to 10.0 ml. Examples
The crystalline free base of lenvatinib (form B) was prepared in accordance with the process disclosed in the patent application WO 2004/101526.
Example 1
Preparation of crystalline lenvatinib phosphate
Crystalline free base of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy- quinoline-6-carboxamide (form B) in the quantity of 203 mg (4.76· 10"4 mol) was dissolved in
3.86 ml of methanol in a hot state. After cooling down to the room temperature, the amount of 35.78 μΐ (5.23· 10"4 mol) of phosphoric acid (85%) was added to this solution under continuous stirring. The mixture was stirred for 12 h at the laboratory temperature. Then, the solvent was left to evaporate in a vacuum drier at the room temperature. UHPLC purity 99.9%. X-ray powder pattern in Fig. 1. Melting point in accordance with DSC 178°C.
Example 2
Preparation of crystalline lenvatinib tartrate
Crystalline free base of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy- quinoline-6-carboxamide (form B) in the quantity of 198 mg (4.64· 10"4 mol) together with 73.84 mg (4.87-10"4 mol) of I-(+)-tartaric acid was dissolved in 3.76 ml of methanol in a hot state. The solution was cooled down to the room temperature under continuous stirring and the mixture was stirred at the laboratory temperature for 12 h. Then, the solvent was left to evaporate in a vacuum drier at the room temperature. UHPLC purity 99.9%. X-ray powder pattern in Fig. 2. Melting point in accordance with DSC 169°C.
Example 3
Preparation of crystalline lenvatinib citrate
Crystalline free base of 4-[3-c oro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy- quinoline-6-carboxamide (form B) in the quantity of 210 mg (4.92-10"4 mol) together with 99.25 mg (5.17-10"4 mol) of citric acid was dissolved in 20 ml of ethyl acetate in a hot state. The solution was cooled down to the room temperature under continuous stirring and the mixture was stirred at the laboratory temperature for 12 h. Then, the solvent was left to evaporate in a vacuum drier at the room temperature. UHPLC purity 99.9%. X-ray powder pattern in Fig. 3. Melting point in accordance with DSC 148°C.
Example 4
Preparation of crystalline lenvatinib camphorsulfonate
Crystalline free base of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy- quinoline-6-carboxamide (form B) in the quantity of 250 mg (5.86-10^ mol) together with 138.83 mg (5.86-10"4 mol) of camphorsulfonic acid (98%) was dissolved in 4.75 ml of methanol in a hot state. The solution was cooled down to the room temperature under continuous stirring and the mixture was stirred at the laboratory temperature for 12 h. Then,
the solvent was left to evaporate in a vacuum drier at the room temperature. UHPLC purity 99.9%. X-ray powder pattern in Fig. 4. Melting point in accordance with DSC 211°C.
Example 5
Preparation of crystalline lenvatinib isethionate
Crystalline free base of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy- quinoline-6-carboxamide (form B) in the quantity of 220 mg (5.15-10"4 mol) together with 68.26 mg (5.41 -10" mol) of isethionic acid was dissolved in 4.18 ml of methanol in a hot state. The solution was cooled down to the room temperature under continuous stirring and the mixture was stirred at the laboratory temperature for 12 h. Then, the solvent was left to evaporate in a vacuum drier at the room temperature. UHPLC purity 99.4%. X-ray powder pattern in Fig. 5. Melting point in accordance with DSC 144°C.
Example 6
Preparation of crystalline lenvatinib naphthalenedisulfonate
Crystalline free base of 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy- quinoline-6-carboxamide (form B) in the quantity of 247 mg (5.79· 10"4 mol) together with 215 mg (5.79· 10"4 mol) of 1,5-naphthalenedisulfonic acid tetrahydrate (97%) was dissolved in 8 ml of methanol in a hot state. The solution was cooled down to the room temperature under continuous stirring and the mixture was stirred at the laboratory temperature for 12 h. Then, the solvent was left to evaporate in a vacuum drier at the room temperature. UHPLC purity 76%. X-ray powder pattern in Fig. 6. Melting point in accordance with DSC 155°C.
Claims
1. A salt of lenvatinib with an acid in a solid form, wherein the acid is selected from the group consisting of phosphoric acid, tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid.
2. The salt with an acid in accordance with claim 1, wherein the acid is phosphoric acid, exhibiting the following characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 8.1; 11.3; 20.3; 21.5 and 25.8 ± 0.2° 2-theta.
3. The salt of lenvatinib with the acid in accordance with claim 2, characterized by the differential scanning calorimetry curve with the melting point at 178°C.
4. A method for preparing the salt of lenvatinib with an acid as defined in claims 1 to 3, characterized in that the free base of lenvatinib is dissolved in a suitable solvent arid phosphoric acid is added subsequently.
5. The method of preparing in accordance with claim 4, characterized in that the suitable solvent is a solvent selected from the group consisting of aliphatic C1-C4 alcohols, ketones, esters, nitriles, water or their mixtures, preferably from acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
6. The salt of lenvatinib with an acid in accordance with claim 1, wherein the acid is tartaric acid, exhibiting the following characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 4.0; 11.1; 15.2; 20.2 and 22.4 ± 0.2* 2-theta.
7. The salt of lenvatinib with the acid in accordance with claim 6, characterized by the differential scanning calorimetry curve with the melting point at 169°C.
8. The salt of lenvatinib with an acid in accordance with claim 1, wherein the acid is citric acid, exhibiting the following characteristic reflections in me X-ray powder1 pattern with the use of CuKa radiation: 8.0; 12.0; 13.9; 20.0 and 24.3 ± 0.2° 2-theta.
9. The salt of lenvatinib in accordance with claim 8, characterized by the differential scanning calorimetry curve with the melting point at 148°C.
10. The salt of lenvatinib with an acid in accordance with claim 1, wherein the acid is camphorsulfonic acid, exhibiting the following characteristic reflections in the X-ray powder pattern with the use of CuK radiation: 4.6; 12.8; 14.4; 16.4; 18.1; 18.5; 20.1 and 25.8 ± 0.2° 2-theta.
11. The salt of lenvatinib with the acid in accordance with claim 10, characterized by the differential scanning calorimetry curve with the melting point at 211 °C.
12. The salt of lenvatinib with an acid in accordance with claim 1, wherein the acid is isethionic acid, exhibiting the following characteristic reflections in the X-ray powder pattern with the use of CuKa radiation: 5.1; 9.4; 14.6; 17.3; 20.1 and 25.4 ± 0.2° 2- theta
13. The salt of lenvatinib with the acid in accordance with claim 1 , characterized by the differential scanning calorimetry curve with the melting point at 144°C.
14. The salt of lenvatinib with an acid in accordance with claim 1, wherein the acid is naphthalenedisulfonic acid, exhibiting the following characteristic reflections in the X- ray powder pattern with the use of CuKa radiation: 5.8; 10.2; 13.5; 15.6; 19.9 and 23.3 ± 0.2° 2-theta.
15. The salt of lenvatinib with the acid in accordance with claim 14, characterized by the differential scanning calorimetry curve with the melting point at 155°C.
16. A method for preparing the salt of lenvatinib with an acid as defined in claims 1 and 6 to 15, characterized in that the free base of lenvatinib is dissolved in a suitable solvent together with the acid that is selected from the group consisting of tartaric acid, citric acid, camphorsulfonic acid, isethionic acid and naphthalenedisulfonic acid.
17. The method of preparing in accordance with claim 16, characterized in that the suitable solvent is a solvent selected from the group consisting of aliphatic C C4 alcohols, ketones, esters, nitriles, water or their mixtures, preferably from acetone, ethyl acetate, acetonitrile, methanol, ethanol, water or their mixtures.
18. Use of the solid form of a salt of lenvatinib with an acid as defined in claims 1 to 3 and 6 to 15 for the preparation of a pharmaceutical composition.
19. A pharmaceutical composition, characterized in that it contains a solid form of a salt of lenvatinib with an acid as defined in claims 1 to 3 and 6 to 15 and at least one pharmaceutically acceptable excipient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2016-240A CZ2016240A3 (en) | 2016-04-27 | 2016-04-27 | Salts of lenvatinib |
| CZPV2016-240 | 2016-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017186197A1 true WO2017186197A1 (en) | 2017-11-02 |
Family
ID=58794020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CZ2017/000030 Ceased WO2017186197A1 (en) | 2016-04-27 | 2017-04-27 | Salts of lenvatinib |
Country Status (2)
| Country | Link |
|---|---|
| CZ (1) | CZ2016240A3 (en) |
| WO (1) | WO2017186197A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110229103A (en) * | 2019-06-27 | 2019-09-13 | 尚科生物医药（上海）有限公司 | A kind of pleasure is cut down for the preparation method of Buddhist nun's Mesylate Form B |
| CN113831283A (en) * | 2021-11-04 | 2021-12-24 | 南京科默生物医药有限公司 | Preparation method of amorphous matter of Ranuncutinib salt |
| CN116120228A (en) * | 2022-12-31 | 2023-05-16 | 江苏希迪制药有限公司 | A kind of high-purity lenvatinib refining method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032872A1 (en) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
| WO2004101526A1 (en) | 2003-04-22 | 2004-11-25 | Eisai Co., Ltd. | Polymorphous crystal of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-qunolinecarboxamide and method for preparation thereof |
| WO2005063713A1 (en) | 2003-12-25 | 2005-07-14 | Eisai Co., Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| WO2006030826A1 (en) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| WO2006137474A1 (en) | 2005-06-23 | 2006-12-28 | Eisai R & D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
| WO2011021597A1 (en) | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Quinoline derivative-containing pharmaceutical composition |
| WO2014098176A1 (en) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Amorphous form of quinoline derivative, and method for producing same |
-
2016
- 2016-04-27 CZ CZ2016-240A patent/CZ2016240A3/en unknown
-
2017
- 2017-04-27 WO PCT/CZ2017/000030 patent/WO2017186197A1/en not_active Ceased
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032872A1 (en) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
| WO2004101526A1 (en) | 2003-04-22 | 2004-11-25 | Eisai Co., Ltd. | Polymorphous crystal of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-qunolinecarboxamide and method for preparation thereof |
| US20070117842A1 (en) * | 2003-04-22 | 2007-05-24 | Itaru Arimoto | Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same |
| WO2005063713A1 (en) | 2003-12-25 | 2005-07-14 | Eisai Co., Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| EP1698623A1 (en) * | 2003-12-25 | 2006-09-06 | Eisai Co., Ltd. | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these |
| WO2006030826A1 (en) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| WO2006137474A1 (en) | 2005-06-23 | 2006-12-28 | Eisai R & D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
| EP1894918A1 (en) * | 2005-06-23 | 2008-03-05 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same |
| WO2011021597A1 (en) | 2009-08-19 | 2011-02-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Quinoline derivative-containing pharmaceutical composition |
| WO2014098176A1 (en) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Amorphous form of quinoline derivative, and method for producing same |
Non-Patent Citations (1)
| Title |
|---|
| CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMIS, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110229103A (en) * | 2019-06-27 | 2019-09-13 | 尚科生物医药（上海）有限公司 | A kind of pleasure is cut down for the preparation method of Buddhist nun's Mesylate Form B |
| CN113831283A (en) * | 2021-11-04 | 2021-12-24 | 南京科默生物医药有限公司 | Preparation method of amorphous matter of Ranuncutinib salt |
| CN113831283B (en) * | 2021-11-04 | 2024-04-19 | 南京科默生物医药有限公司 | Preparation method of lenvatinib salt amorphous substance |
| CN116120228A (en) * | 2022-12-31 | 2023-05-16 | 江苏希迪制药有限公司 | A kind of high-purity lenvatinib refining method |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2016240A3 (en) | 2017-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410189B2 (en) | Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production | |
| CN110494423B (en) | Novel crystal form of lenvatinib mesylate and preparation method thereof | |
| EP3243824A1 (en) | Solid forms of ibrutinib free base | |
| WO2017008773A1 (en) | Crystalline forms of obeticholic acid | |
| WO2017174044A1 (en) | Solid forms of ibrutinib | |
| CA2928287A1 (en) | Solid form of axitinib | |
| CZ201682A3 (en) | Solvated crystalline forms of olaparib, their preparation and use | |
| EP3256474B1 (en) | Ibrutinib sulphate salt | |
| WO2017186197A1 (en) | Salts of lenvatinib | |
| WO2018046028A1 (en) | Solid forms of eluxadoline | |
| WO2016127963A1 (en) | Solid forms of palbociclib salts | |
| US12202834B2 (en) | Solid state forms of oclacitinib maleate | |
| WO2018113801A1 (en) | Crystalline forms of2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation | |
| CZ201769A3 (en) | Solid forms of Venetoclax | |
| CZ2014708A3 (en) | Bedaqujiline salts | |
| WO2017016529A1 (en) | Solid forms of ceritinib free base | |
| CZ2015442A3 (en) | Ibrutinib hemisulfate | |
| EA030029B1 (en) | STABLE POLYMORPH OF THE SALT OF (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE WITH L-TARTARIC ACID | |
| CZ2016222A3 (en) | Solid forms of the salts of the obeticholic acid | |
| EP3372592A1 (en) | Solid forms of lesinurad amine salts | |
| CZ2015641A3 (en) | Ceritinib salts | |
| CZ2017646A3 (en) | Benzoic acid co-crystal (3α, 5ß, 6α, 7α) -6-ethyl-3,7-dihydroxycholan-24-acid | |
| CZ2015522A3 (en) | Solid forms of the free base of ceritinib | |
| CZ2015743A3 (en) | Solid forms of the free base of ceritinib | |
| CZ2015391A3 (en) | Salt of bedaquiline with citric acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17726184 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17726184 Country of ref document: EP Kind code of ref document: A1 |